Furthermore, combining OX40 agonists and cancer vaccines can generate effective anti-tumor immune responses against nuclear proteins that are difficult to target with small molecule inhibitors or monoclonal antibodies. The gene discussed is TNFRSF4; the disease is neoplasm.